Skip to main content
. 2014 Jan 21;28(1):19–25. doi: 10.3341/kjo.2014.28.1.19

Fig. 4.

Fig. 4

Patient distribution in the intravitreal bevacizumab injection group with respect to change in visual acuity (VA) differences as measured using a Snellen chart at each follow-up (FU) interval. The levels reflect gain or loss of Snellen chart lines compared with baseline VA.